STA-4783 and Paclitaxel for Treatment of Solid Tumors
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, toxicity and maximum tolerated dose of
single doses of STA-4783/paclitaxel in combination when administered intravenously to
patients with refractory cancer. To determine the pharmacokinetics of STA-4783 and paclitaxel
when co-administered.
To assess the anti-tumor activity of STA-4783 and paclitaxel when co-administered.